Does end-of-treatment FDG-PET improve outcomes in follicular lymphoma?

Affiliations

¹ Department of Radiology and Nuclear Medicine, Academic Medical Center, University of Amsterdam, 1105AZ Amsterdam, Netherlands. Electronic address: h.j.a.adams@gmail.com.
² Department of Radiology, Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Groningen, Netherlands.

Comment

Hugo J A Adams et al. Lancet Oncol. 2019 Jan.

. 2019 Jan;20(1):e4.

doi: 10.1016/S1470-2045(18)30866-0.

¹ Department of Radiology and Nuclear Medicine, Academic Medical Center, University of Amsterdam, 1105AZ Amsterdam, Netherlands. Electronic address: h.j.a.adams@gmail.com.
² Department of Radiology, Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Groningen, Netherlands.

No abstract available

Comment in

Does end-of-treatment FDG-PET improve outcomes in follicular lymphoma? - Authors' reply.
Trotman J, Barrington SF, Meignan M; PET investigators from the GALLIUM study. Trotman J, et al. Lancet Oncol. 2019 Jan;20(1):e5. doi: 10.1016/S1470-2045(18)30933-1. Lancet Oncol. 2019. PMID: 30614478 No abstract available.

Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial.
Trotman J, Barrington SF, Belada D, Meignan M, MacEwan R, Owen C, Ptáčník V, Rosta A, Fingerle-Rowson GR, Zhu J, Nielsen T, Sahin D, Hiddemann W, Marcus RE, Davies A; PET investigators from the GALLIUM study. Trotman J, et al. Lancet Oncol. 2018 Nov;19(11):1530-1542. doi: 10.1016/S1470-2045(18)30618-1. Epub 2018 Oct 8. Lancet Oncol. 2018. PMID: 30309758